<DOC>
	<DOCNO>NCT00858468</DOCNO>
	<brief_summary>Primary Objective : To describe safety 2004-2005 pediatric formulation inactivate , split-virion influenza vaccine Fluzone® , give two-dose schedule ( described package insert vaccine-naïve young child ) investigational control group . Observational Objective : To describe percentage protective Hemagglutination Inhibition ( HAI ) antibody titer ( follow 2-dose Fluzone® immunization series ) 3 vaccine antigen among investigational control group .</brief_summary>
	<brief_title>Safety Immunogenicity Testing Influenza Vaccine Healthy Children 2 Months 6 Months Age</brief_title>
	<detailed_description>This observational descriptive study provide preliminary comparative information safety immunogenicity Fluzone® vaccine among child age 6 12 week ( investigational group , also refer 2-month-old group ) versus child age 24 36 week ( control group , also refer 6-month-old group ) . The study design achieve preset statistical power , hypothesis test .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 42 84 day ( 6 12 week ) 24 36 week day inclusion . Born full term pregnancy ( ≥ 36 week ) birth weight ≥ 2.5 kg . Considered good health basis report medical history historydirected physical examination . Available duration study . Parent/guardian willing able provide inform consent . Parent/guardian able attend schedule visit comply trial procedure . Willingness permit venipuncture heel stick purpose collect blood sample . Exclusion Criteria : Reported allergy egg protein , chicken protein constituent vaccine . Previous history influenza vaccination document history influenza infection . Receipt vaccine 7 day prior enrollment . An acute illness fever ( rectal temperature ≥ 38.0 °C [ ≥ 100.4 °F ] ) 72 hour precede enrollment trial ( defer enrollment ) . Known bleed disorder . Participation clinical trial within 30 day prior enrollment , plan participation another clinical trial prior termination subject 's participation study . Known suspect impairment immunologic function receipt immunosuppressive therapy immunoglobulin since birth . Personal immediate family history congenital immune deficiency . Developmental delay , neurologic disorder , seizure disorder . Chronic medical , congenital developmental disorder could interfere trial conduct completion . Known HIVpositive HBsAgpositive mother . Known HIV , hepatitis B ( HBsAg ) , hepatitis C infection . Blood bloodderived product receive past 2 month . Prior history GuillainBarré syndrome . Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>